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Background: Genome-wide studies have begun to link subtle variations in both allelic DNA methylation and
parent-of-origin genetic effects with early development. Numerous reports have highlighted that the placenta
plays a critical role in coordinating fetal growth, with many key functions regulated by genomic imprinting.
With the recent description of wide-spread polymorphic placenta-specific imprinting, the molecular mechanisms
leading to this curious polymorphic epigenetic phenomenon is unknown, as is their involvement in pregnancies
complications.
Results: Profiling of 35 ubiquitous and 112 placenta-specific imprinted differentially methylated regions (DMRs)
using high-density methylation arrays and pyrosequencing revealed isolated aberrant methylation at ubiquitous
DMRs as well as abundant hypomethylation at placenta-specific DMRs. Analysis of the underlying chromatin state
revealed that the polymorphic nature is not only evident at the level of allelic methylation, but DMRs can also
adopt an unusual epigenetic signature where the underlying histones are biallelically enrichment of H3K4
methylation, a modification normally mutually exclusive with DNA methylation. Quantitative expression analysis
in placenta identified two genes, GPR1-AS1 and ZDBF2, that were differentially expressed between IUGRs and
control samples after adjusting for clinical factors, revealing coordinated deregulation at the chromosome 2q33
imprinted locus.
Conclusions: DNA methylation is less stable at placenta-specific imprinted DMRs compared to ubiquitous
DMRs and contributes to privileged state of the placenta epigenome. IUGR-associated expression differences
were identified for several imprinted transcripts independent of allelic methylation. Further work is required to
determine if these differences are the cause IUGR or reflect unique adaption by the placenta to developmental
stresses.
Keywords: Imprinting, Placenta, DNA methylation, Epigenetics* Correspondence: dmonk@idibell.cat
†Ana Monteagudo-Sánchez and Marta Sánchez-Delgado contributed equally
to this work.
1Imprinting and Cancer Group, Cancer Epigenetics and Biology Program,
Bellvitge Biomedical Research Institute – IDIBELL, Av. Gran Via de
L’Hospotalet 199-203, 08907 L’Hospitalet de Llobregat, Barcelona, Spain
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Monteagudo-Sánchez et al. Clinical Epigenetics           (2019) 11:35 Page 2 of 15Background
In developed countries, intrauterine growth restriction
(IUGR) is commonly associated with underlying placen-
tal insufficiency that prevents the fetus from achieving
its full growth potential. Often confused with small for
gestational age (SGA), IUGR is classified as aberrant
growth in utero, whereas SGA refers to a newborn with
a birth weight below the tenth centile for gestational age
of the pregnancy [1]. The mechanisms leading to IUGR
are not well defined and can be multifactorial. However,
IUGR is clinically associated with increased umbilical or
uterine artery resistance in prenatal Doppler measures, in-
dicative of anomalies in placental vasculature. Abnormal
remodelling of spiral arteries by invading trophoblast cells
of the placenta is associated with pre-eclampsia (PE) [2].
Often pregnancies complicated by IUGR or PE are accom-
panied by prematurity, since early elective delivery is war-
ranted to limit fetal distress [3]. In addition, IUGR babies
not only have immediate medical problems requiring
extensive stay in neonatal units but are at increased risk of
common comorbidities later in life, including hyperten-
sion, type 2-diabetes, and heart disease through the effects
of fetal programming [4].
The molecular mechanisms and genes involved in IUGR
and PE are largely unknown. Changes in epigenetic modi-
fications, including DNA methylation and histone modifi-
cations, have been suggested to play a role, contributing to
stable alterations of gene expression. These epigenetic
aberrations not only act as candidate biomarkers but may
be maintained long after the initial developmental insult
shaping metabolic phenotypes later in life [5].
In mammals, imprinted genes are known to regulate
placental development, fetal growth and have recently
been implicated in the aetiology of PE [6]. These genes
are expressed in a parent-of-origin manner and are be-
lieved to have co-evolved with placentation [7].
Imprinted genes are associated with multiple layers of
epigenetic regulation, including DNA methylation and
histone tail modifications that results in their monoalle-
lic expression [8]. Classically imprinted domains are
regulated in cis by differentially methylated regions
(DMRs) inheriting their methylation from the gametes
that act as imprinting control regions (ICR). Several
studies in humans have investigated changes in expression
and regulation of imprinted genes in placentas from co-
horts with heterogeneous clinical characteristics (healthy
pregnancies, PE, SGA, and IUGR), suggesting that deregu-
lation of this group of genes might play a role in regulating
prenatal growth and development [9–12]. In addition, the
epigenetic marks associated with imprinted genes have
been shown to be particularly susceptible to variation fol-
lowing the use of assisted reproductive techniques [13],
with initial studies in mice suggesting that methylation in
the placenta is particularly vulnerable [14].Recently several groups, including ours, have identified
widespread placenta-specific imprinting which is restricted
to humans [15–18]. Unlike conventional imprinting for
which methylation at DMRs is normally ubiquitously
observed in all tissues, placenta-specific imprinting is asso-
ciated with transient germline DMRs inherited from the
oocyte, present only in pre-implantation embryos and the
placenta. This is in contrast to ubiquitous DMRs which
can be either germline or somatically acquired. Further-
more, initial reports suggest that placenta-specific
DMRs maybe polymorphic varying in frequency among
individuals [16, 17].
We have carried out a comprehensive genome-wide
profiling of bona fide ubiquitous and placenta-specific
imprinted genes in a large collection of well-characterised
placenta samples to address if aberrant methylation is
associated with IUGR or PE. Furthermore, we looked for
expression differences accounting for the IUGR. Lastly,
we investigated the molecular mechanisms accounting
for polymorphic imprinting observed at placenta-
specific DMRs by comparing multiple epigenetic




In a cohort of 127 placenta samples, 40 with correspon-
ding maternal and cord blood samples were collected at
the Hospital St. Joan De Deu (Barcelona, Spain), all of
which had undergone microsatellite repeat analysis to
confirm they were free of maternal DNA contamination
(Additional file 1). For all samples, multiple sampling from
the fetal side around the cord insertion site was taken,
although for the majority of experiments only a single
biopsy was used.
Chorionic villus sampling (CVS) from singleton gesta-
tions was obtained from Hospital Clinic Barcelona that
subsequently resulted in normal live births at term.
Following delivery, a term placenta biopsy was also col-
lected. Both DNA and RNA extraction, as well as cDNA
synthesis, were carried as previously described [19].
Methylation array hybridization for 5mC analysis
We generated methylation datasets for 22 placenta sam-
ples using the Illumina Infinium Human Methylation450
BeadChip arrays, which simultaneously quantifies ~ 1.7%
of all CpG dinucleotides. Two paired CVS-term placenta
samples were hybridized to the Infinium MethylationE-
PIC (EPIC) arrays since the former platform was made
obsolete in 2017, as were the samples from multiple ana-
tomical sites and twin/triplet pregnancies. Bisulphite
conversion was performed according to the manufac-
turer’s recommendations for the Illumina Infinium
Assay (EZ DNA methylation kit, ZYMO, Orange, CA).
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wing the Illumina Infinium HD methylation protocol at
genomic facilities of the Cancer Epigenetics and Biology
Program (Barcelona, Spain).
Data filtering and analysis of methylation signals
In addition to the HM450k datasets generated in-house,
we also included 45 placenta sample datasets (31 pre-
eclampsia and 14 term controls), from GSE57767, which
were collected at Hospital of the University of Pennsylvania
(Additional file 1) [20]. Before analyzing the data, we
excluded possible sources of technical biases that could
influence results. We applied signal background sub-
traction, and inter-plate variation was normalised using
default control probes in BeadStudio (version
2011.1_Infinium HD). We discarded probes with a
detection p value > 0.01, containing single nucleotide
polymorphisms (SNPs) within the interrogation or
extension base as well as those with potential
cross-reaction due to multiple sequence homologies.
We also excluded probes that lacked signal values in
one or more of the DNA samples analyzed. For the
analysis of known imprinted domains, only probes
mapping to DMRs with confirmed allelic methylation
were examined. For samples hybridized to the EPIC,
only probes present on the HM450k platform were ana-
lyzed. In-house bioinformatics R scripts were utilized
for statistical comparisons.
Statistical analyses
Differences between groups were checked by two-tailed
unpaired Student’s t tests or Mann-Whitney-Wilcoxon
tests depending on data distribution. These differences
were considered significant at p < 0.05. The similarity be-
tween methylation profiles was measured by the Pearson
correlation coefficients. For multiple comparisons, we
used Benjamini and Hochberg corrections. All clinical
data were introduced in a Statistical Package for Social
Sciences (SPSS, IBM) software v17.0 database. Variables
showing associations that were significant in the univa-
riant analysis were subsequently introduced in multiple
regression models to adjust for possible interactions or
confounding factors. Results were considered significant
if the p value < 0.05.
Genotyping and imprinting analysis
Genotypes of potential SNPs were identified by interro-
gating the hg19 genome build on the UCSC sequence
browser and confirmed by PCR and direct sequencing.
Sequence traces were interrogated using Sequencher
v4.6 (Gene Codes Corporation, MI) to distinguish het-
erozygous and homozygous samples. Heterozygous
tissue samples were used for subsequent molecular tech-
nique that required allelic discrimination, includingallelic RT-PCR, bisulphite PCR, and ChIP, with the SNP
base incorporated into the PCR product (for primer
sequences, see Additional file 2).
RT-PCR analysis
Microfluidic-based quantitative expression analysis
Oligonucleotide primer sequences were designed using
the Universal ProbeLibrary Assay Design Center on the
Roche Resource webpage that also identified the appro-
priate UPL probe sequences for each amplicon (for pri-
mer sequences, see Additional file 2). First-strand cDNA
for 50 placenta samples (a subset of those analyzed by
pyrosequencing) was generated using supplier’s proto-
cols for 50 ng of total RNA, which were subsequently
pre-amplified (also referred to as specific target amplifi-
cation; STA) for 14 cycles with a multiplexed pool of
primers using the PreAmlification Master Mix (Fluidigm
100-5581). Subsequently, gene-specific RT-PCRs were
performed with the same primers and specific UPLs on
a Fluidigm 96.96 Dynamic Arrays using the Biomark HD
system (Fluidigm Corp.) according to manufacturer’s in-
structions. The relative expression was quantified using
the 2−ΔΔCt method and represented as fold change in
gene expression normalised to the mean of the house-
keeping gene RPL19 and the mean of all placentas. Only
samples with two or more valid readings per triplicate
were included.
Standard qRT-PCR
One microgram of RNA from 50 control samples from
uncomplicated pregnancies was used to generate cDNA
using random priming. These samples were used to de-
termine the normal range of placental expression for
H19, IGF2, MEST, and SNU13 using SYBR Green mix-
ture (SYBR® Green) on a 7900HT Fast Real-Time PCR
(Applied Biosystems) instrument.
Bisulphite methylation analyses
Allelic PCR: For standard bisulphite conversion, we used
the EZ DNA Methylation-Gold kit (Zymo) following the
manufacturer’s instructions. Approximately 2 μl of
bisulphite-converted DNA was used in each amplifica-
tion reaction using Immolase Taq polymerase (Bioline)
for 45 cycles and the resulting PCR product sub-cloned
into a pGEM-T easy vector (Promega) for sequencing
(for primer sequences see Additional file 2).
Pyrosequencing: Standard bisulphite PCR was used to
determine the methylation in a confirmatory cohort (see
Additional file 1 for details). Standard amplification of
50 ng of bisulphite-converted DNA was used with the
exception that one primer was biotinylated (for primer
sequence see Additional file 2). The entire biotinylated
PCR product (diluted to 40 μl) was mixed with 38 μl of
binding buffer and 2 μl (10 mg/ml) streptavidin-coated
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denaturated with 50 μl 0.5 M NaOH. The single-
stranded DNA was hybridized to 40-pmol sequencing
primers dissolved in 11 μl annealing buffer at 90 °C. For
sequencing, a primer was designed to the opposite
strand to the biotinylated primer used in the PCR reac-
tion. The pyrosequencing reaction was carried out on a
PyroMark Q96 instrument. The peak heights were deter-
mined using Pyro Q-CpG1.0.9 software (Biotage).
Chromatin immunoprecipitations (ChIP)
ChIP on native chromatin was performed as previously
described [21]. Essentially, ~ 100mg of placenta tissue was
disrupted to release nuclei using 0.5mM zirconium beads
(Sigma-Aldrich) in a Precellys 24 tissue homogenizer
(Berton_Corp) which were subsequently isolated by
centrifugation. The nuclei were subject to MNase
digestion (15 units/ul who) for between 1 and 3 min
and aliquots run on agarose gels to select digest with
the most abundant mono- and pento-nucleosome frac-
tions. Approximately 4 μg of chromatin was used for an
immunoprecipitation reaction with protein A agarose/
salmon sperm DNA (Thermo Fisher) and a H3K4me3
(Diagenode, C15410003-50), H3K4me2 (Millipore,
07-030), and H3K9me3 (Abcam, AB8898) antibodies.
Each ChIP was performed alongside a mock immuno-
precipitation with an unrelated IgG antiserum (12–371,
Millipore), and a 50% fraction of the input chromatin
was extracted in parallel. Before use in downstream
experiments, control allelic precipitation at ubiquitous
DMRs (MEST and SNURF) confirmed the quality of the
ChIP material.
For quantitative analysis, the input and antibody-bound
fractions were subject to real-time PCR amplification with
a SYBR Green mixture (SYBR® Green) using a Quant
Studio 5 or 7900HT Fast Real-Time PCR (Applied Biosys-
tems) instrument. Background precipitation levels were
determined from the mock precipitations with a non-
specific IgG antiserum. Bound/input ratios were calcu-
lated and were normalised against the precipitation level
at the GAPDH promoter for active marks and SAT2
repeats for H3K9me2/3. All PCRs reactions were per-
formed three times in triplicate. The primers used are
listed in Additional file 2.
Results
Aberrant methylation at ubiquitous DMRs is associated
with IUGR
Using the Illumina Infinium Human Methylation450
BeadChip arrays (HM450k) array platform, we initially
profiled ubiquitous imprinted DMRs in 67 placenta
samples. A total of 601 probes located within 35 ubi-
quitous DMRs passed quality control and were assessed
in all samples. Overall, the methylation at these regionswas extremely stable in control placentas and those
from complicated pregnancies with no differences
detected between groups. We identified isolated
gain-of-methylation (GOM) at two DMRs associated
with the MEST and MCTS2 genes in a control biopsy
(PL35) and an IUGR placenta (PL37), respectively. In
addition, we observed multiple cases with partial
loss-of-methylation (LOM) at the H19 and SNU13
DMRs. The three samples with hypomethylation of the
H19 ICR (PL67, 90, 217) were all from pregnancies com-
plicated by IUGR, whereas the four samples with aberrant
SNU13 methylation were from IUGR (PL90), SGA
(PL4002), and pre-eclampsia (PL2048, 2026)(Fig. 1a;
Additional file 3).
Subsequently, we tested a second cohort of samples by
quantitative pyrosequencing (n = 127, 109 not analyzed
on HM450k platform) and confirmed the array observa-
tions (Fig. 1b). Interestingly, additional cases of H19 ICR
(PL78 and 41) and SNU13 (PL78, 146) hypomethylation
were detected in this extended sample set. This also
revealed that there were no differences in methylation
for any DMR when comparing the IUGR, SGA, and
pre-eclampsia groups with controls and that previously
identified hypomethylated samples were all in the lower
quartile. To ensure that the isolated methylation ano-
malies were epigenetic in origin and not associated with
chromosomal aberrations, the presence of micro-
deletions or uniparental disomy were discounted using
both standard polymorphic short tandem repeats and
multiplex ligation-dependent probe amplification ana-
lyses (Additional file 4).
We have previously shown that the H19 gene has a
unique methylation profile in placenta compared to
somatic tissues with the paternal allele-specific methyla-
tion extending from the core ICR and throughout the
gene body [22]. To determine if the LOM we observed
at the H19 ICR is restricted to this interval, or is more
widespread, we performed pyrosequencing for the pro-
moter and gene body. This revealed that the partial hy-
pomethylation was generally uniform throughout the
interval (Fig. 1b). Hypomethylation of the paternal allele
of the H19 ICR is associated with the pre- and postnatal
growth disorder Silver-Russell syndrome (SRS; OMIM
180860) [23]. Interestingly, all aberrant methylation pro-
files for the four DMRs were restricted to the placenta
as corresponding cord blood samples were in the normal
range, suggesting that the patients are not classic
imprinting disorders (Fig. 1c).
Hypomethylation of H19 results in biallelic expression
of the H19 non-coding RNA and the concomitant
decrease of expression of IGF2. Using RT-PCR and
Sanger sequencing in samples heterozygous for a SNP in
exon 5, we observe LOM at H19 results in the reactiva-
tion of the normally repressed paternal allele (Fig. 1d, e),
Fig. 1 (See legend on next page.)
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Fig. 1 Analysis of imprinted methylation at ubiquitous DMRs using HM450k methylation arrays. a The left side is a heatmap of absolute
methylation (β values) for individual Infinium probes mapping to 35 DMRs in 67 placenta samples. Samples with abnormal methylation
across a DMR are highlighted by yellow boxes. The right side of the figure reveals methylation difference according to severity, with blue
and red representing hypo- and hypermethylation, respectively. Samples are classified by both the presence of pre-eclampsia (black yes;
gray no) and fetal growth parameters (appropriate for gestational age light gray; SGA dark gray; IUGR black). *Adjacent to the DMR name
indicates somatic establishment of methylation. b Pyrosequencing confirmation of the aberrant methylation profiles identified using HM450k arrays, as
well as the quantification of additional placenta samples. The violin plots used include the median (white dot) and the interquartile range
(black rectangle), with hypomethylated samples identified using the HM450k array platform highlighted as green data points, while hypermethylated
samples are in red. The non-parametric Mann-Whitney-Wilcoxon test was used to calculate the statistical significance of the differences between IUGR
and control groups (ns indicated no significance, p > 0.05). c Pyrosequencing quantification in cord blood samples. The violin plots show
the distribution of methylation for 16 controls. Samples with aberrant placenta methylation profiles are highlighted. d Quantitative RT-PCR
for transcripts regulated by affected DMRs. The violin plots represent the expression levels of 50 control placenta samples with normal birthweight and
methylation. Samples with hypomethylation are highlighted as green data points, while hypermethylated samples are in red. e Allelic expression
analysis was performed for the H19 transcript using the rs2839704 SNP, with allelic contributions quantified by pyrosequencing
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50 control placenta samples (hypomethylated mean
0.51 ± 0.38 SD vs control mean 2.49 ± 1.6 SD, p < 0.01).
Furthermore, the samples with SNU13 LOM were
among the samples with most abundant expression and
the single placenta sample with MEST GOM was the
lowest expressed (Fig. 1d). Due to the small number of
samples with these isolated methylation aberrations, we
could not perform additional statistical comparisons.
Allelic studies could not be performed for the SNU13
LOM samples due to the lack of heterozygosity for
exonic SNPs.
Polymorphic events at placenta-specific DMRs are not
more frequent in pregnancy complications
We utilized the same Illumina Infinium HM450K array
data to explore the profiles of placenta-specific DMRs.
In total, we analyzed 112 regions incorporating 763
probes, which represents the total number of confirmed
placenta-specific DMRs from our previous work [15, 16]
and those reported in two additional studies [17, 18].
Consistent with previous reports, this revealed that the
majority of placenta-specific DMRs have some samples
with low-level methylation, indicative of a polymorphic
event (Fig. 2a; Additional file 3).
To confirm these observations, 32 placenta-specific
DMRs associated with paternal expression were analyzed
by pyrosequencing. For two loci, AIM1 and N4BP2L1,
we found significant differences between the mean
methylation levels for the IUGR group compared to con-
trols (IUGR mean 66.5% vs control mean 63.0%, p 0.038;
IUGR mean 52.5% vs control mean 48.6%, p 0.046,
respectively). No significant differences were observed
between pre-eclampsia samples and controls (Fig. 2b,
Additional file 5). After separating groups by gender, two
genes AIM1 and RHOBTB3 showed a statistically signifi-
cant (p < 0.05), but biologically very small difference in
percentage methylation, with higher levels observed in
IUGR females. However, these differences did notwithstand Benjamini and Hochberg correction for mul-
tiple testing (Additional file 5). In addition to comparing
the mean methylation for each group, we also deter-
mined the number of placenta samples lacking methyla-
tion at each placenta-specific DMR. Using the ± 1.5
interquartile range (1.5 IQR) to determine outliers, we
observed no differences in the frequency of these poly-
morphic events, with equal numbers of hypomethylated
samples distributed between the IUGR and control
groups (Fig. 2; Additional file 5). For some regions, such
as THAP3 and R3HCC1, there were two distinct popula-
tions one with low-level methylation (52% and 53% of
the samples, respectively), not detected as outliers, and
those maintaining partial methylation indicative of a
DMR (Fig. 2; Additional file 6).
Placenta-specific DMRs maintain methylation across
gestation
One possible mechanism leading to the apparent poly-
morphic placenta-specific DMRs is the failure to maintain
allelic methylation during gestation. For a temporal
comparison, we performed methylation profiling using
the EPIC methylation arrays on first trimester CVS
and compared with corresponding samples at term.
This revealed that DNA methylation level at placenta-
specific DMRs is stable between the two points with
higher correlations at placenta-specific DMRs (mean
Pearson’s r = 0.88; range 0.85–0.90) than between un-
related placenta samples (mean Pearson’s r = 0.76;
range 0.64–0.89) (Additional file 7). Detailed scrutiny
of the paired samples revealed that the DMRs show-
ing polymorphic LOM were maintained from first
trimester to term but diverged between individuals
(Additional file 7). In addition, to ensure that the
methylation profiles observed were uniform across the
placental plate, we determined the placenta-specific
DMR profiles from multiple biopsies from the same
term placentas. Biopsies collected from the opposite
sides of the cord insertion site also showed higher
A
B
Fig. 2 Analysis of imprinted methylation at placenta-specific DMRs using HM450k methylation arrays. a The left side is a heatmap of absolute
methylation (β values) for individual Infinium probes mapping to 112 DMRs in 67 placenta samples. The right side of the figure reveals outlier
samples as identified by > 1.5 IQR (red) and < 1.5 IQR (blue) methylation values, respectively. Samples are classified by both the presence
of pre-eclampsia (black yes; gray no) and fetal growth parameters (appropriate for gestational age light gray; SGA dark gray; IUGR black)
b Pyrosequencing confirmation of the aberrant methylation profiles identified using HM450k arrays, as well as the quantification of the
extended placenta cohort. The violin plots include the median (white dot) and the interquartile range (black rectangle); samples with
hypomethylation defined by < 1.5 IQR are highlighted as green data points. Placenta-specific DMRs with a distinct population of lowly
methylated samples not identified by IQR statistic are highlighted in yellow. The non-parametric Mann-Whitney-Wilcoxon test was used to
calculate the significance of the differences between IUGR and control groups (ns indicated no significance, p > 0.05)
Monteagudo-Sánchez et al. Clinical Epigenetics           (2019) 11:35 Page 7 of 15correlations (mean Pearson’s r = 0.95; range 0.95–0.96)
than between unrelated placenta samples suggesting
that methylation does not vary greatly between sam-
pling sites. Finally, we compared placenta samples
from dizygotic twins and triplets. This revealed that
the correlations between samples of the same gesta-
tions, therefore sharing the same in utero environ-
ment and maternal exposures, were also more similar(mean Pearson’s r 0.83; range 0.82–0.85) than be-
tween unrelated samples.
Altered allelic histone modification profile is associated
with biallelic expression
During our initial description of placenta-specific im-
printing, we observed that polymorphic biallelic expres-
sion was associated with two different scenarios. The
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ting in the absence of imprinting. The second more
complicated and rare event was associated with main-
tained maternal methylation [16]. This suggests that a
subset of these DMRs do not influence allelic expression
or that the expression arises from an alternative pro-
moter. Since our previous searches failed to identify
transcripts originating from upstream promoters in
placenta, we favor the first option.
To understand the role of additional epigenetic mecha-
nisms in the polymorphic placenta-specific imprinting, we
studied post-translational modifications of histones using
ChIP. After extensive allelic methylation and expression
analyses of samples in our cohort, two regions, LIN28B
and R3HCC1, were selected for in-depth ChIP analysis.
The maternally methylated region upstream of the
LIN28B gene presents with lack of methylation in ~ 12%
of samples. Interestingly, one of the samples lacking
methylation, PL216, comes from a multiple gestation
pregnancy with the dizygotic twin sibling (PL215) having
a normal methylation profile at this locus, indicating
that the maternal environment is not responsible for
these differences (Additional file 8). For samples with
maintained LIN28B imprinting (Fig. 3a), qPCR on ChIP
material revealed enrichment for both active (H3K4me2
and H3K4me3) and repressive histone modifications
(H3K9me2 and H3K9me3), which was shown to be on
opposing chromosomes using allelic PCR (Fig. 3b, c).
However, in the sample that was biallelically unmethylated,
we observed increased enrichment of active histone marks
on both parental chromosomes, while the amount of
precipitation of repressive marks was largely unchanged.
In the case of the R3HCC1 DMR, we identified sam-
ples with the three situations associated with poly-
morphic imprinted expression. One placenta with
monoallelic expression and maternal methylation
(PL30) and two others with biallelic expression, the
first one of them with the expected ~ 50% methylation
at the DMR (PL62) and the other lacking allelic
methylation (PL98) (Fig. 3d). As expected, qPCR on
ChIP material from control placenta samples with
maternal methylation and monoallelic expression revealed
opposing enrichment for the active (H3K4me2 and
H3K4me3) and repressive histone (H3K9me2) modifica-
tions. However, in the samples with biallelic expression,
active marks were enriched on both parental chromo-
somes, irrespective of allelic methylation status (Fig. 3e, f ).
Expression levels of imprinted genes are associated with
IUGR
We have previously shown that significant differences in
expression of transcripts are often independent of
imprinted DMR methylation [24, 25]. To determine if
absolute expression levels are associated with IUGR, weperformed microfluidic-based quantitative RT-PCR ana-
lysis for genes associated with 22 ubiquitous and 13
placenta-specific DMRs. Unfortunately, we did not have
sufficient samples with pre-eclampsia to perform statis-
tical analysis. To identify genes significantly differentially
expressed between IUGR and control samples, we car-
ried out unpaired two-tailed t tests (p < 0.05). This
revealed that only three ubiquitously imprinted genes
were significantly differentially expressed; ZNF331 was
higher in IUGRs compared to controls (IUGR mean 1.32
vs control mean 0.78, p = 0.041), whereas PEG10 (IUGR
mean 1.05 vs control mean 1.57, p = 0.047) and ZDBF2
(IUGR mean 0.98 vs control mean 1.5, p = 0.029) were
significantly lower (Fig. 4e; Additional file 9). Four
placenta-specific imprinted transcripts were also diffe-
rentially expressed; ADAM23 (IUGR mean 0.62 vs con-
trol mean 1.25, p = 0.004), GPR1-AS1 (IUGR mean 0.87
vs control mean 1.55, p = 0.022), LIN28B (IUGR mean
1.01 vs control mean 1.36, p = 0.046), and ZHX3 (IUGR
mean 0.56 vs control mean 1.16, p = 0.004) all being less
abundant in the IUGR population (Additional file 9).
Differences in IUGR-associated expression can be
influenced by fetal gender [24]. We analyzed expression
after separating the groups according to sex. Surpri-
singly, we observe that for five of the seven genes with
expression differences (PEG10, ZDBF2, ADAM23,
LIN28B, and ZHX3), the effect was primarily due to
lower transcript abundance in the IUGR male group
(Additional file 9). Furthermore, after separating by gen-
der, we noticed a difference not identified in the popula-
tion as a whole, with DNMT1 (IUGR mean for males
0.62 vs control mean for males 1.42, p = 0.004) and
INPPF5 (IUGR mean for the placenta of males 0.87 vs
mean control males 1.42, p = 0.018) being less abun-
dant in IUGR males compared to controls, while
GRB10, a potent growth inhibitor, is higher in IUGR
males (IUGR mean for males 0.98 vs control mean for
males 0.62, p = 0.026) (Additional file 9).
Clinical factors that were different between the IUGR
and control groups as well as those that seem to be asso-
ciated to the expression of each gene were explored
(Additional file 10). Once the confounders (gestational
age and birth weight, fetal gender, ART, and maternal
characteristics) were controlled for by linear regression,
only changes in ZDBF2 and GPR1-AS1 were associated
with IUGR. For LIN28B and ZHX3, the results of the
univariate analysis seemed to be explained by a con-
founding effect of gestational age.
Downregulation of the GPR1-AS1-ADAM23 imprinted
domain in IUGR
Three of the genes showing altered expression in our
IUGR population, GPR1-AS1, ZDBF2, and ADAM23, are






Fig. 3 (See legend on next page.)
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Fig. 3 Detailed characterization of histone modifications within placenta-specific DMRs in samples with polymorphic imprinting. Schematic
representation of a the LIN28B loci, indicating the position of transcripts and CpG islands incorporating the DMRs. The methylation of the two
placenta samples analyzed was assessed by bisulphite PCR and sub-cloning. Each circle represents a single CpG on a DNA strand. (•) methylated
cytosine, (o) unmethylated cytosine. Each row corresponds to an individual cloned sequence with the genotype indicated for the heterozygous
SNP incorporated into the amplicon. b Quantitative PCR targeting the LIN28B DMR in ChIP material. Precipitations were normalised to GAPDH
promoter (H3K4me2/3) and SAT2 repeats (H3K9me2/3). The graphs represent the mean values (± standard deviation). For each placenta sample,
values are the mean of at least three independent ChIP experiments, each in triplicate. c The allelic distribution of each mark was determined by
direct sequencing of the PCR product encompassing the heterozygous SNP used for the methylation analysis. The percentage of allelic enrichment is
shown under the electropherograms. d Diagram of the R3HCC1 loci and the methylation bisulphite PCR profiles of the three analyzed samples. e, f The
quantitative and allelic ChIP results for the R3HCC1 DMR, respectively, which were analyzed in the same way as for LIN28B
Monteagudo-Sánchez et al. Clinical Epigenetics           (2019) 11:35 Page 10 of 152q33 imprinted cluster (Fig. 4a). This domain is highly
conserved between mammals. Studies in mice show that
imprinting is dependent on a maternal germline
placenta-specific Gpr1-as DMR, which subsequently
influences the expression of the long isoform of Zdbf2
(Liz), orthologous to GPR1-AS1 in humans [26]. The Liz
transcript is responsible for the in cis regulation of the
paternally methylated DMR upstream of the canonical
Zdbf2 promoter during embryogenesis [27]. The ob-
served downregulation we note in our placenta cohort
suggests that there could be a synchronised deregulation
throughout this domain in IUGR, which is supported by
the moderate correlation between the expression of
GPR1-AS1 and ZDBF2 (Pearson’s r = 0.38, p 0.001). To
further investigate the possible mechanisms involved in
this coordinated regulation, we confirmed the allelic
methylation of the two DMRs, as well as characterising
the epigenetic profile for the promoter CpG islands as-
sociated with ZDBF2 and ADAM23. This revealed that
in placenta, the promoters of ZDBF2 and ADAM23 are
devoid of methylation, GPR1-AS1 is maternally methyl-
ated as previously reported (26), and ZDBF2 is prefe-
rentially methylated on the paternal allele (Fig. 4b).
Furthermore, interrogation of the histone modifications
located in these intervals revealed allelic enrichment of
permissive marks on the expressed allele at the
ADAM23 promoter and GRP1-AS1 DMR, with the later
also decorated with H3K9me3 on the maternal allele.
Only allelic H3K9 methylation was observed within the
ZDBF2 DMR (Fig. 4d, e). Unfortunately, we could not
perform allelic ChIP within the ZDBF2 promoter be-
cause of the lack of informative SNPs. Finally, we per-
formed pyrosequencing to quantify the methylation at
the two DMRs. No differences were observed between
the means of the IUGR and control groups (Fig. 4f ),
with all samples being appropriately methylated, indi-
cating that the variance in expression levels is inde-
pendent of allelic methylation.
Discussion
Abnormal placentation is responsible for numerous preg-
nancy complications including infertility, miscarriage, PE,and IUGR. Pre-eclampsia may manifest alongside IUGR
[28] and both normotensive IUGR and PE are associated
with a deficient invasion of specific extra-villous tropho-
blast. This results in the limited transfer of nutrients and
exchange of waste products between the two genetically
distinct individuals, fetus and mother, which have conflic-
ting needs. Studies of imprinted genes in mouse models
have revealed that they regulate growth in a manner that
balances the supply and demand of maternal nutrients
[29], with some paternally expressed genes driving fetal
growth and maternally expressed genes restricting it via
limiting resource allocations. Whilst not all imprinted
genes support this hypothesis, it is endorsed by reports of
increased expression of CDKN1C, a maternally expressed
growth repressor [30], as well as lower paternal IGF2 in
SGA and IUGR placenta samples [9–11, 25, 31, 32]. In
some cases, the genes have been proposed to influence
fetal growth early in development, with significant growth
correlations only observed in first trimester samples and
not term, while others, including PHLDA2, are classified
as late growth effectors with the largest impact observed
at term [11].
For the majority of studies, to date, very few have
assessed both methylation and expression in a genome-
wide manner to determine the role of imprinting on
pregnancy outcome (reviewed in [8]). Here, we describe
the first large-scale assessment of methylation and
expression at both ubiquitous and placenta-specific
imprinted domains. This revealed that although rare,
isolated LOM at ubiquitous DMRs can occur and does
directly influence expression. We observe hypomethyla-
tion of H19 in placenta, but not cord blood, associated
with low levels of IGF2 and concomitant H19 biallelic
expression in four IUGR cases. Such epimutations are
normally associated with SRS, for which there is com-
parable hypomethylation between blood-derived DNA
and placentas [33]. This isolated placenta H19 hypome-
thylation is likely reflecting non-syndromic IUGR and
not SRS. Consistent with this hypothesis, the individuals
attain a low score using the Netchine-Harbison clinical
criteria [34, 35] and exhibit post-natal catch-up growth
once the constraints of the placenta were removed at
Fig. 4 (See legend on next page.)
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Fig. 4 Epigenetic and transcriptional description of the GPR1-AS1-ADAM23 locus in IUGR placentas. a Schematic representation of the GPR1-AS1-
ADAM23 imprinted locus on chromosome 2, indicating the position of the transcripts and CpG islands incorporating the DMRs. b Characterization
of the DMRs and promoter CpG islands in placenta biopsies. Each circle represents a single CpG on a DNA strand. (•) methylated cytosine, (o)
unmethylated cytosine. Each row corresponds to an individual cloned sequence with the genotype indicated for heterozygous SNP incorporated
into the amplicon. c Quantitative PCR on ChIP material. Precipitations were normalized to GAPDH promoter (H3K4me2/3) and SAT2 repeats
(H3K9me2/3). The graphs represent the mean values (± standard deviation). For each placenta sample, values are the mean of at least three
independent ChIP experiments, each in triplicate. d The allelic distribution of each mark was determined by direct sequencing of the PCR
product encompassing heterozygous SNPs. e Quantification of expression levels of GPR1-AS1, ZDBF2, and ADAM23 using microfluidic-based
RT-qPCR. The results are presented as violin plots, with the median (white dot), mean (red line), and the interquartile range (black rectangle)
shown. All expression levels were normalised to the mean of the RPL19 housekeeping gene. To determine the statistical significance of the
difference between the IUGR and control groups, Student’s two-tailed t test was used and p values are indicated over the horizontal comparison
lines. f Pyrosequencing quantification of the GPR1-AS1 and ZDBF2 DMRs. The violin plots include the median (white dot) mean (red line) and
the interquartile range (black rectangle). The non-parametric Mann-Whitney-Wilcoxon test was used to calculate the statistical significance of
the differences between IUGR and control groups (ns indicated no significance, p > 0.05)
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events are also involved in fetal growth, as hypomethyla-
tion of the MCTS2P DMR has been observed at a low
frequency in large control cohort studies [36], but both
H19 hypomethylation and MEST hypermethylation have
previously been linked to SGA/IUGR.
Several studies have determined links between
imprinted gene expression and aberrant fetal growth
parameters, several of which were also identified in
this study. Diplas and colleagues noted an association
between ZNF331 and PEG10 abundance and fetal growth
and IUGR [37], with subsequent work from the same
group linking expression of other imprinted transcripts
and growth [32, 38]. Strong negative correlations between
GRB10 expression in the placenta and head circum-
ference, but not birth weight, have also been reported
[11], which is consistent with our observations and mouse
models suggesting that this gene is a negative regulator of
fetal growth [39]. Our study also revealed that gender-
specific differences in expression are frequently associated
with IUGR. Such effects have previously been reported for
the PLAGL1 gene although the effect was restricted to
females rather than males [24]. Consistent with the
current study, the expression differences also occurred
without a change in allelic methylation suggesting an
involvement of transcription factor binding or underlying
chromatin structure. Three of the seven genes with
IUGR-associated differences were located within the
GPR1-AS1-ADAM23-imprinted domain on chromosome
2. Imprinting of this region is regulated by the maternally
methylated GPR1-AS1 DMR, which is unique in that it
regulates the acquisition of methylation on the paternal
allele of the ZDBF2 DMR [26, 27]. We observe a non-
canonical imprinted histone signature for this region in
placenta, an observation reported in mouse brain [27].
Targeted truncation of the Gpr-as1/Liz transcript by
polyA cassette insertion results in concomitant decrease
in Zdbf2 abundance and postnatal growth restriction with-
out affecting allelic methylation at Gpr1-as DMR [40].This growth effect was evident towards the end of ges-
tation and is consistent with the decreased expression that
we observe throughout the domain in our IUGR samples.
One limitation of this study is the use of a single
biopsy from the fetal side of the placenta. Recently, it
was shown that the expression of PHLDA2 was signifi-
cantly increased at distal sampling sites compared with
sites close to the umbilical cord [41]. Through the use
of consistent sampling, great care was taken to ensure
that the sampling sites were similar between samples.
reassuringly, we did not observe great variability in
methylation between multiple biopsies from the same
placenta (Additional file 7) suggesting that variation
would be minimal.
The recent description of hundreds of placenta-
specific DMRs, which are largely restricted to the human
[16], suggests that imprinting may have gained a signifi-
cantly more instrumental role during evolution and
careful characterization is required to dissect if they
influence fetal growth. Critically, these placenta-specific
maternally methylated DMRs are polymorphic in nature,
a feature not observed at classic ubiquitous imprinted
DMRs. Analysis of our placenta cohort from normal and
complicated gestations revealed a similar frequency in
polymorphic hypomethylation, implying that these regions
may not influence fetal growth. However, there seems to
be a subset of placenta-specific DMRs that do not show
methylation variability, suggesting they are tightly regu-
lated. Interestingly, the polymorphic nature is not only
evident at the level of allelic methylation, as biallelic
expression was observed at regions maintaining allelic
methylation. In these rare divergent samples, our observa-
tions suggest some DMRs can adopt an unusual under-
lying histone signature with biallelic enrichment of H3K4
methylation. However, this histone modification is nor-
mally mutually exclusive with DNA methylation and fur-
ther work is required to ensure that the observed pattern
is not due to different epigenetic profiles in heterogeneous
cells of the placenta.
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variability between gestations, it is currently unknown
if this reflects polymorphic establishment in individual
oocytes or erratic maintenance during embryonic re-
programming. To fully address these issues, single-cell
experiments will need to be performed. Alternatively,
this relaxation of allelic methylation may reflect the
placenta’s ability to accommodate to early physiological
conditions, with the variability observed as a conse-
quence of the adaptive nature of the privileged placenta
epigenome. Since genomic imprinting arises early in
development, the variability we observe may serve as a
biosensor for the impact of in utero environmental and
maternal exposures. Environmental contaminants have
been associated with subtle epigenetic changes [42];
therefore, it would be interesting to determine whether
variability in placenta-specific DMR methylation changes
with exposure, for example, to air pollutants or maternal
smoking habits that have been shown to effect final fetal
size [43–45]. However, our analysis in multiple gestation
pregnancies suggests that the profile of polymorphic
placenta-specific imprinting may simply indicate a ran-
dom event rather than reflecting exposure.Conclusions
While the clinical manifestations associated with classic
imprinting disorders has aided our understanding of the
relevance of these genes in development, such cases are
extremely rare. To date, few studies have examined the
impact of subtler epigenetic variation in target tissues
such as the placenta on allelic expression of imprinted
transcripts in a way reminiscent of GWAS studies which
have revealed the influence of genetic variation on
growth [46]. With potentially hundreds of placenta-
specific DMRs that could influence allelic expression,
and their polymorphic nature, much work is required to
understand how they impact the placenta’s key role
during pregnancy. It will be imperative that future work
discriminates between those placenta-specific imprinted
transcripts that have little biological relevance, being a
by-product of inherited methylation differences from the
gametes, from those exerting an effect on pregnancy and
that influence long-term adult phenotypes.Additional files
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